Evercore Wealth Management LLC maintained its stake in shares of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 107,091 shares of the biotechnology company’s stock at the end of the second quarter. Evercore Wealth Management LLC owned about 0.21% of Infinity Pharmaceuticals worth $168,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of INFI. Highbridge Capital Management LLC acquired a new position in Infinity Pharmaceuticals in the 1st quarter valued at about $106,000. Ameriprise Financial Inc. acquired a new position in Infinity Pharmaceuticals in the 2nd quarter valued at about $130,000. LMR Partners LLP acquired a new position in Infinity Pharmaceuticals in the 2nd quarter valued at about $222,000. Wells Fargo & Company MN increased its position in Infinity Pharmaceuticals by 144.6% in the 1st quarter. Wells Fargo & Company MN now owns 81,493 shares of the biotechnology company’s stock valued at $263,000 after acquiring an additional 48,177 shares during the period. Finally, Citadel Advisors LLC increased its position in Infinity Pharmaceuticals by 19,074.1% in the 1st quarter. Citadel Advisors LLC now owns 86,522 shares of the biotechnology company’s stock valued at $279,000 after acquiring an additional 86,978 shares during the period. Hedge funds and other institutional investors own 67.47% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/09/30/infinity-pharmaceuticals-inc-infi-stake-held-by-evercore-wealth-management-llc.html.

Separately, ValuEngine cut Infinity Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st.

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) opened at 1.33 on Friday. Infinity Pharmaceuticals, Inc. has a 12 month low of $0.84 and a 12 month high of $3.84. The firm’s market cap is $67.42 million. The company has a 50-day moving average price of $1.15 and a 200 day moving average price of $1.83.

Infinity Pharmaceuticals (NASDAQ:INFI) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.12). During the same period in the previous year, the business posted $1.05 EPS. Equities research analysts anticipate that Infinity Pharmaceuticals, Inc. will post ($0.92) EPS for the current year.

About Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.

Institutional Ownership by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Stock Ratings for Infinity Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.